SeekingAlpha · Feb 17, 2026
Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript
Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call February 17, 2026 11:00 AM ESTCompany ParticipantsCarl Spana - Co-Founder, President, CEO &...
AMEX · PTN
Healthcare · Biotechnology
$9.47
Up+$0.53 (+5.60%)
Updated Aug 14, 2026, 12:51 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PTN closed at $9.47 after 20 trading sessions, up 11.74% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $7.6274 | $9.58 | $7.2701 | $9.47 | 180.24K |
| Aug 11, 2026 | $7.74 | $7.74 | $7.3701 | $7.41 | 6.92K |
| Aug 10, 2026 | $7.76 | $8.20 | $7.28 | $7.36 | 12.81K |
| Aug 7, 2026 | $8.30 | $8.30 | $7.451 | $7.77 | 18.28K |
| Aug 6, 2026 | $8.35 | $8.3999 | $7.61 | $7.8701 | 4.4K |
| Aug 5, 2026 | $8.34 | $8.5082 | $7.60 | $7.94 | 8.1K |
| Aug 4, 2026 | $8.4261 | $8.4261 | $7.90 | $8.01 | 11.05K |
| Aug 3, 2026 | $7.925 | $8.30 | $7.8301 | $8.23 | 12.19K |
| Jul 31, 2026 | $8.20 | $8.20 | $7.58 | $7.70 | 5.85K |
| Jul 30, 2026 | $8.18 | $8.57 | $7.49 | $7.81 | 14.1K |
| Jul 29, 2026 | $8.01 | $8.5052 | $7.61 | $8.08 | 8.49K |
| Jul 28, 2026 | $8.09 | $8.165 | $7.21 | $7.68 | 6.81K |
| Jul 27, 2026 | $7.72 | $8.3087 | $7.72 | $7.81 | 13.35K |
| Jul 24, 2026 | $8.17 | $8.245 | $7.54 | $7.7052 | 8.62K |
| Jul 23, 2026 | $8.01 | $8.36 | $8.00 | $8.0346 | 5.5K |
| Jul 22, 2026 | $8.51 | $8.51 | $8.10 | $8.15 | 5.14K |
| Jul 21, 2026 | $8.69 | $8.77 | $8.47 | $8.62 | 6.1K |
| Jul 20, 2026 | $8.95 | $8.95 | $8.47 | $8.48 | 11.33K |
| Jul 17, 2026 | $8.59 | $9.09 | $8.04 | $9.09 | 23.49K |
| Jul 16, 2026 | $9.515 | $9.79 | $8.26 | $8.475 | 11.59K |
The latest Smart Investors Daily articles mentioning PTN.
PTN research
Company profile and research snapshot.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 12, 2025 | Laidlaw & Co. | Buy | — |
| Feb 13, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 7, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 29, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 28, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Feb 17, 2026
Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call February 17, 2026 11:00 AM ESTCompany ParticipantsCarl Spana - Co-Founder, President, CEO &...
Benzinga · Feb 17, 2026
Palatin Techs (AMEX:PTN) reported quarterly losses of $(2.86) per share which missed the analyst consensus estimate of $(2.69) by 6.12 percent. This is a 2283.33 percent decrease over losses of $(0.12) per share from the
Benzinga · Dec 11, 2025
Palatin Technologies saw an 8.41% after-hours stock price increase following a Janus Henderson Group 13G filing revealing a 9.99% ownership stake in the company.
247wallst.com · Dec 3, 2025
Pre-Market Stock Futures: The futures are trading higher on Wednesday after a stellar day across Wall Street on Tuesday. All of the major indices finished the day higher, with the technology-heavy NASDAQ leading the way, closing up 0.59% at 23,413. The S&P 500 ended the session at 6,829, up 0.25% and the Dow Jones Industrials... Here Are Wednesday's Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy's and More.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning PTN.